Chronic oral therapy with enalapril in normal ponies.

The research article investigates the impact of using enalapril, an angiotensin converting enzyme (ACE) inhibitor, in horses. The study found that enalapril use did not alter behavior, affect reproductive performance, suppress ACE activity, or impact the physical condition of ponies.

Research Purpose and Methodology

• The main purpose of this research was to study the effects of enalapril on horses. Specifically, it aimed to investigate if this medication changes the behavior of stallions or affects their ACE activity. This became important as enalapril is commonly used to treat cardiac diseases in humans, dogs, and cats but has also been observed to cause impotence in humans.
• The research engaged twelve pony stallions for the study. These animals were divided into two groups, with one group receiving enalapril treatment (0.5mg/kg) every 24 hours, while the other received a placebo over a period of two months.
• The researchers collected blood samples after one month of treatment to monitor intragroup ACE activity. Additionally, physical examinations and echocardiographies were conducted before and after the trial period to track any changes in the physical health or reproductive performance of the animals.

Findings and Conclusions

• Upon studying the results at the end of the two-month period, the researchers found no significant changes in terms of physical examinations, echocardiographic indices, or reproductive performance in either group. They also noted that there was no suppression of ACE activity as a result of enalapril usage.
• This lack of observable effect led the researchers to suggest two possible explanations. The first is that the drug may have been poorly absorbed in the horse’s system. Alternatively, the drug may not have been adequately converted into enalaprilat, its active form.
• These findings indicate that, at least at the doses used in this study, enalapril may not be effective in horses. The researchers suggest that further work is necessary to determine if increased dosages, alternative administration methods, or other factors might provide a successful path forward.